Weekly update|Companies|Recruiting|Promote|Post a job

Ikena Oncology

Founded: 2016

Location: Boston, MA

Employee range: 11 - 50

Clinical stage: Clin1

Therapy area: Oncology

Drug types: ONC

Lead product: IK-930

Product link: https://ikenaoncology.com/pipeline/

Funding: $40M stock May 2023; $144M IPO Mar 2021; $120M B Jan 2021; $80M Jan 2019; $49M Dec 2017

Investors: Celgene

ikenaoncology.com

linkedin.com

job board

Short description:

Immuno-Oncology

Drug notes:

IK-175 Clin1 bladder cancer (Partner: BMS), Clin1 head & neck cancer (partner: BMS); IK-595 Clin0 oncology; 2 undisclosed programs Clin0 oncology

Long description:

Ikena Oncology is a clinical-stage biopharmaceutical company developing novel targeted therapies intended to enable a personalized approach for every patient with cancer. The company's pipeline includes programs that target key signaling pathways that drive the formation and spread of cancer, as well as programs targeting the tumor microenvironment. Ikena's lead product candidate, IK-930, is a TEAD inhibitor targeting the Hippo signaling pathway. The Hippo signaling pathway plays a critical role in regulating cell growth and survival. When the Hippo signaling pathway is disrupted, cancer cells can grow and spread uncontrollably. Ikena also has a number of other programs in preclinical and early clinical development.

Jobs:

Main

Contact: recruit@workinbiotech.com